Cytostatics for acromegaly

1987 ◽  
Vol 116 (3) ◽  
pp. 347-349 ◽  
Author(s):  
A. A. Kasperlik-Zaluska ◽  
J. Wislawski ◽  
J. Kaniewska ◽  
J. Zborzil ◽  
E. Frankiewicz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Visual Field ◽  
Ct Scan ◽  
Tumour Growth ◽  
Pituitary Tumour ◽  
Hormone Concentration ◽  
Serum Growth Hormone ◽  
X Ray ◽  
Transcranial Approach ◽  
Symptoms And Signs

Abstract. A 21-year-old woman suffering from acromegaly was treated with transsphenoidal subtotal hypophysectomy (microscopy: acidophilic adenoma), followed by x-ray and bromocriptine therapy. Seven years later she was re-operated because of a partial bitemporal loss of vision, intracranial hypertension, and regrowth of the pituitary tumour seen on CT-scan. A large part of the invasive suprasellar tumour was then removed by transcranial approach. The neurosurgery was followed by cobalt radiotherapy and bromocriptine administration. Two years later, symptoms and signs of tumour growth reappeared. Administration of cytostatics, such as doxorubicin (Adriamycin®) and lomustine (Belustine®), resulted in distinct clinical improvement associated with a seven-fold decrease in the serum growth hormone concentration. The visual field became normal and the intracranial mass on a CT scan decreased markedly. As a result the patient was able to resume work.

Effect of Chlorpromazine on Serum Growth-Hormone Concentration in Man

1971 ◽  
Vol 284 (2) ◽  
pp. 72-74 ◽  
Author(s):  
Lawrence Sherman ◽  
Sooseng Kim ◽  
Fred Benjamin ◽  
Howard D. Kolodny
Keyword(s):  
Growth Hormone ◽  
Hormone Concentration ◽  
Serum Growth Hormone ◽  
Growth Hormone Concentration ◽  
Serum Growth Hormone Concentration

Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal

1992 ◽  
Vol 126 (2) ◽  
pp. 179-183 ◽  
Author(s):  
Jean-Louis Sadoul ◽  
Antoine Thyss ◽  
Pierre Freychet
Keyword(s):  
Growth Hormone ◽  
Tumour Growth ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Clinical Signs ◽  
Treatment Protocol ◽  
Pituitary Tumour ◽  
Prolactin Secretion ◽  
Close Monitoring ◽  
Complete Control

Octreotide and bromocriptine were used to treat an acromegalic patient harbouring an invasive pituitary tumour secreting growth hormone and prolactin. Octreotide (100 μg, subcutaneously, three times daily) and bromocriptine (15 mg orally, daily) rapidly improved clinical signs and symptoms, including diabetes that initially required insulin. Complete control of growth hormone and prolactin secretion was obtained and maintained by this treatment protocol for 12 months without affecting the other pituitary functions. A major tumour shrinkage was apparent by magnetic resonance imaging after six months, and was considered to be complete after 12 months of treatment. Octreotide was then discontinued without any relapse in either growth hormone secretion or tumour growth over a 20-month period following withdrawal. Attempts were made to discontinue bromocriptine, but a maintenance therapy (2.5 mg daily) was required to control rebounds of prolactin hypersecretion. Two months after octreotide withdrawal, acute pancreatitis secondary to cholelithiasis required surgery; this complication was attributed to octreotide (pre-treatment ultrasonography was normal). These findings suggest that combination therapy with octreotide and bromocriptine may be considered in pituitary macroadenomas secreting growth hormone and prolactin. They also emphasize the need for a close monitoring of cholelithiasis, not only during octreotide therapy but also after the drug's withdrawal.

ACTH-producing carcinoma of the pituitary with haematogenic metastases

1997 ◽  
pp. 176-180 ◽  
Author(s):  
AF Garrao ◽  
LG Sobrinho ◽  
MJ Bugalho ◽  
JM Boavida ◽  
JF Raposo ◽  
...  
Keyword(s):  
Ct Scan ◽  
White Woman ◽  
Sphenoid Sinus ◽  
Tumour Growth ◽  
Optic Chiasm ◽  
Pituitary Tumour ◽  
Plasma Acth ◽  
Acth Concentration ◽  
Very High ◽  
Suprasellar Extension

The case report is presented of a 47-year-old white woman with Cushing's disease treated by bilateral adrenalectomy in June 1981. A first computed tomography (CT) scan in September 1984 showed a voluminous pituitary adenoma with invasion of the sphenoid sinus and left parasellar extension. The tumour increased progressively in size, a suprasellar extension developed and the optic chiasm was eventually affected. In March 1988 and June 1989 the patient underwent two surgeries for the pituitary tumour, the second followed by radiotherapy. During this period, the ACTH values varied between 100 pmol/l and 403 pmol/l (normal: < 13 pmol/l). After radiotherapy, a progressive shrinking of the tumour was observed and the ACTH concentrations decreased to a lowest value of 27.5 pmol/l. The patient was clinically well until September 1993 when, suddenly, the plasma ACTH concentration increased to very high levels (greater than 965 pmol/l). There was no evidence of tumour growth on the sellar CT scan. In January 1995, an ACTH-producing pituitary carcinoma was diagnosed, based on the presence of bone metastases. The patient died in May 1995.

scholarly journals Serum growth hormone levels and size of pituitary tumour in untreated acromegaly

BMJ ◽  
1969 ◽  
Vol 4 (5683) ◽  
pp. 582-584 ◽  
Author(s):  
A. D. Wright ◽  
M. S. F. McLachlan ◽  
F. H. Doyle ◽  
T. R. Fraser
Keyword(s):  
Growth Hormone ◽  
Pituitary Tumour ◽  
Serum Growth Hormone ◽  
Hormone Levels

EFFECT OF BROMOCRIPTINE, ERGOTAMINE AND OTHER ERGOT ALKALOIDS ON THE HORMONE SECRETION AND GROWTH OF A RAT PITUITARY TUMOUR

1980 ◽  
Vol 86 (1) ◽  
pp. 147-153 ◽  
Author(s):  
R. A. PRYSOR-JONES ◽  
J. S. JENKINS
Keyword(s):  
Growth Hormone ◽  
Inhibitory Action ◽  
Tumour Growth ◽  
Hormone Secretion ◽  
Ergot Alkaloids ◽  
Pituitary Tumour ◽  
Rat Pituitary ◽  
Dopaminergic Mechanisms ◽  
Excessive Secretion

The effect of bromocriptine on hormone secretion and the growth of the prolactin- and growth hormone (GH)-secreting rat pituitary tumour of the GH3 cell line has been compared with that of ergotamine and other ergot alkaloids. Bromocriptine in doses ranging from 1 to 20 mg/kg had no effect on tumour growth or on the excessive secretion of GH by the tumour; prolactin concentrations were reduced only by the highest dosage of the drug. Similarly the tumour was resistant to the administration of ergocryptine, ergocornine and the synthetic ergolines, lergotrile and CH 29–717. In contrast, ergotamine reduced secretion of both GH and prolactin and considerably inhibited the growth of the tumour. Experiments in vitro showed that ergotamine inhibited DNA synthesis of the tumour cells and decreased hormone secretion. It was concluded that ergotamine had a direct inhibitory action on the GH3 cell tumour which was not mediated through the dopaminergic mechanisms.

The effect of growth hormone on pituitary tumour growth

2010 ◽  
Vol 17 (4) ◽  
pp. 365-368 ◽  
Author(s):  
Roselle Herring ◽  
David Russell–Jones
Keyword(s):  
Growth Hormone ◽  
Tumour Growth ◽  
Pituitary Tumour

Conversion of CSF monomeric growth hormone to large growth hormone with exposure to serum

1986 ◽  
Vol 111 (3) ◽  
pp. 289-295 ◽  
Author(s):  
D. Alan Nixon ◽  
Richard M. Jordan ◽  
Nancy M. Tresp
Keyword(s):  
Growth Hormone ◽  
Serum Proteins ◽  
Venous Drainage ◽  
Gel Chromatography ◽  
Hormone Concentration ◽  
Serum Growth Hormone ◽  
Growth Hormone Concentration ◽  
Elution Pattern ◽  
Large Growth ◽  
A Site

Abstract. We have found a dissociation between CSF and serum growth hormone heterogeneity in a patient with suprasellar extension of a growth hormone-secreting pituitary tumour. When CSF was studied using gel chromatography, virtually all the growth hormone eluted as monomeric growth hormone with only 2.4% eluting before albumin as large growth hormone ('big, big' growth hormone). In contrast, the large component comprised 15.4% of the total immunoreactivity in simultaneously obtained serum. When the CSF specimen was incubated with growth hormone-poor serum, the elution pattern changed remarkably with 16% of the total immunoreactivity eluting as large growth hormone causing it to resemble the serum elution pattern. We also measured growth hormone heterogeneity in the inferior petrosal vein (a site very close to pituitary venous drainage) during inferior petrosal venography in 3 patients. As the growth hormone concentration increased, the percentage eluting as monomeric growth hormone increased, whereas that eluting as large growth hormone decreased. When the growth hormone concentration fell towards baseline, the percentage of growth hormone eluting as monomeric growth hormone fell while that eluting as large growth hormone increased. Thus, our studies suggest that large growth hormone results from binding of monomeric growth hormone to serum proteins or aggregation of monomeric growth hormone in the presence of protein. Our studies also show that when blood is sampled at a site close to the pituitary, the growth hormone is released primarily as monomeric growth hormone.

Sign in / Sign up

Export Citation Format

Share Document